Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 8/20 | 0.33 |
| ▸ | CTSS | P25774 | 7/20 | 0.33 |
| ▸ | CTSL | P07711 | 4/20 | 0.33 |
| ▸ | CTSB | P07858 | 6/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7187100 | 1.00 | POLB (0.36) | POLBCTSKCTSSCTSLCTSB | |
| SCHEMBL8104148 | 1.00 | POLB (0.36) | POLBCTSKCTSSCTSLCTSB | |
| SCHEMBL7187098 | 1.00 | POLB (0.36) | POLBCTSKCTSSCTSLCTSB | |
| SCHEMBL9175389 | 0.78 | POLB (0.36) | POLBCTSKCTSSCTSLCTSB | |
| SCHEMBL9358907 | 0.78 | POLB (0.38) | POLBCTSKCTSSCTSLCTSB | |
| SCHEMBL7032979 | 0.77 | POLB (0.35) | POLBCTSKCTSSCTSLCTSB | |
| SCHEMBL5440575 | 0.77 | POLB (0.35) | POLBCTSKCTSSCTSLCTSB | |
| SCHEMBL11497664 | 0.77 | POLB (0.35) | POLBCTSKCTSSCTSLCTSB | |
| SCHEMBL11452540 | 0.77 | POLB (0.35) | POLBCTSKCTSSCTSLCTSB | |
| SCHEMBL11497665 | 0.77 | POLB (0.35) | POLBCTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059018-A1 | COVALENTLY BINDING IMAGING PROBES | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | disclosed |
| US-6071899-A | Azetidinone derivatives for the treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-06-06 | — | — | US | disclosed |
| WO-1996013484-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059018-A1 | COVALENTLY BINDING IMAGING PROBES | CTSV, CTSL, CTSE | POLB 1749/4885CTSK 20/4885CTSS 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.